BD (Becton, Dickinson and Company) announced it will hold an audio webcast on November 5, 2026, at 8 a.m. ET to discuss its financial results for the fourth quarter and full fiscal year 2026, which ended September 30, 2026. The webcast will also provide updates on the company's operations and strategy. Prior to the call, BD will release a news statement and presentation materials summarizing the financial information. This event is important for investors to understand BD's recent performance and future outlook in the medical technology sector.
BDX, a major player in the health sector, has a market cap of $49.07 billion and offers a dividend yield of 2.33%, reflecting its stable income potential. As of October 9, 2026, 03:22 WIB, BDX shares trade at USD 182.49 on Pluang, up 1.29% in the last day. This trading activity provides a current market context as BD prepares to announce its fiscal 2026 results on November 5, 2026.
Barclays initiated coverage of Becton, Dickinson and Company (BDX) with an "Underweight" rating, indicating a cautious outlook for the medical technology stock. BDX is partnering with the U.S. government to boost domestic manufacturing and strengthen...
BD (Becton, Dickinson and Company) celebrated 65 years of manufacturing syringes in Canaan, Connecticut, where it produces over 2 billion syringes annually. The site, which started in 1961 with 8 employees, now employs over 500 people and has expande...
BD (Becton, Dickinson and Company) has appointed Ferass Abuzaina as the worldwide president of its Surgery business unit, effective immediately. Abuzaina will lead the global strategic, operational, and commercial efforts of the Surgery division from...
BD (Becton, Dickinson and Company) announced a major partnership with the U.S. government to invest $19 billion in expanding domestic manufacturing of essential medical consumables. This initiative aims to strengthen healthcare supply chains, increas...
